SavedAdd your journal

Journals / Kartal Eğitim ve Araştırma Hastanesi Tıp Dergisi / 2003 / Cilt: 14 - Sayı: 2

Comparison of timolol and latanoprost in patients with ocular hypertension and primary open angle glaucoma

Oküler hipertansiyon ve primer açık açılı glokom hastalarında timolol ve latanoprostun karşılaştırılması

Ekrem KURNAZ
Yusuf ÖZERTÜRK
Burak ÖZDEMİR
Pages
81–84
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

IOP was significantly (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Glaucoma is one of the most important causes of irreversibl blindness.
📊
Key Findings & Data:In this 3 months prospective, randomized study 44 patients with PAOG or OHT received either 0,5% timolol twice daily (at 9:00 AM and 9:00 PM) or 0,05% latanoprost once daily (at 09:00 AM).
💡
Conclusion & Impact:IOP was significantly (p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Glaucoma is one of the most important causes of irreversibl blindness. We present this study to compare intraocular pressure (lOP)-lowering efficacy of timolol or latanoprost monomerapy in patients with primary open angle glaucoma (POAG) and ocular hypertension (OHT). In this 3 months prospective, randomized study 44 patients with PAOG or OHT received either 0,5% timolol twice daily (at 9:00 AM and 9:00 PM) or 0,05% latanoprost once daily (at 09:00 AM). Change in mean diurnal IOP after 3 months of treatment was compared with baseline measurements and between groups. The mean baseline IOP level was 25,0+1,8 mmHg in timolol group (22 patients) and was 24,7±2,1 mmHg in latanoprost group (22 patients). IOP was significantly (p

Özet

Glokom irreversibl körlüğün en sık sebeplerindendir. Bu çalışmada oküler hipertansiyon (OHT) ve primer açık açılı glokom (PAAG) hastalarında timolol ve latanoprost monoterapilerinin göz içi basıncı (GİB) üzerine etkilerini karşılaştırma amaçlanmıştır. OHT ve PAAG teşhisli 44 hasta, 3 aylık prospektif çalışmaya alındı. Hastalar günde İM defa (saat 9:00,21:00) %0,5 timolol ve günde tek doz (saat 21:00) %0,005 latanoprost gruplarına randomize edildi. 3 ay takip sonunda ilaçların bazal GİB'na kıyasla sağladıkları GİB düşüş değerleri karşılaştırıldı. Timolol monoterapisi başlanan 22 hastada başlangıç ortalama diumal GİB değeri 25,0±1,8 mmHg iken, latanoprost monoterapisi başlanan 22 hastada 24,7±2,1 mmHg idi. Her iki ilaç da 3 aylık tedavi süresince GİB değerlerinde anlamlı derecede düşüş sağladı (p

🔖

Cite This Article

KURNAZ, E., ÖZERTÜRK, Y., ÖZDEMİR, B. (2022). Comparison of timolol and latanoprost in patients with ocular hypertension and primary open angle glaucoma. Kartal Eğitim ve Araştırma Hastanesi Tıp Dergisi, Cilt: 14 - Sayı: 2, 81–84. https://ajindex.com/articles/571570

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Camras CB, Schumer RA, Marsk A, et al. Intraocular pressure reduction with PhXA34, a new prostoglandin analogue, in patients with ocular hipertension. Arch Ophtalmolog 1992; 110: 1733-8
  2. Villumsen J, Alm A. PhXA34-a prostaglandin F2a anologue. Effects on intraocular pressure in patients with ocular hypertension. Br J Ophtalmol 1992; 76: 214-7
  3. Toris CB, Camras CB, Yablonski ME. Effects of PhXA41, a new prostoglandin F2a analogue, on aqueous humour dynamics in human eyes. Ophtalmology 1993; 100: 1297-304
  4. Strernschantz J, Resul B. Phenyl substituted prostoglandin analogs for glaucoma treatment. Drugs Future 1992; 17: 691-704
  5. Alm A, Villumsun J. PhXA41 a new potent ocular hypotensive drug. A study on dose response relationship and on aqueous humor dynamics in healty volunteers. Arch Ophtalmol 1991;109: 1564-8
  6. Nilsson SFE, Samuelson M, Bill A, Stjernschantz J. Increased uveoscleral outflow as possible mechanism of ocular hypotension caused by prostaglandin F2a 1-isopropylester in cynomolgus monkey. Exp Eye Res 1989; 48: 707-16
  7. Crawford K, Kaufman PL. Pilocarpine antagonizes prostaglandin F2a induced oculer hypotension in monkeys. Evidence for enhancement of uveoscleral outflow by prostaglandin F2a. Arch Ophtalmol 1987; 105: 1112-6
  8. Gabelt BT, Kaufman PL. Prostaglandin F2a increses uveoscleral outflow in cynomolgus monkey. Exp Eye Res 1989; 49: 389-402
  9. Ziai N, Dolan JW, Kacere RD, Brubaker RF. The effects on aqueous humor dynamics of PhXA41, a new prostaglandin F2a analogue, after topical aplication in normal and ocular hypertensive human eyes. Arch Ophtalmol 1993; 111: 1351-8
  10. Camras CB, Wax MB, Ritch R, et al. Latanoprost treatment for glaucoma: Effects of treating for 1 year and of switching from timolol. United States Latanoprost Study Group. Am J Ophtalmol 1998; 126: 390-9
  11. Camras CB, Alm A, Watson P, Sternjschantz J. Latanoprost, a prostaglandin anologue, for glaucoma therapy. Efficacy and safety after a year treatment in 198 patients. Latanoprost Study Groups. Ophtalmology 1996; 103: 1916-24
  12. Alm A, Strenschantz J. Effects on intraocular pressure and side effects of %0,005 latanoprost applied once daily, evening or morning. A comparision with timolol. Scandanavian Latanoprost Study Group. Ophtalmology. 1995; 102: 1743-52
  13. Camras CB. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma. Ophtalmology 1996;103: 138-47
  14. Mishima HK, Masuda K, Kitazawa Y, et al. A compariso